PPARα activation promotes liver progenitor cell-mediated liver regeneration by suppressing YAP signaling in zebrafish
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
PPARα activation promotes liver progenitor cell-mediated liver regeneration by suppressing YAP signaling in zebrafish ; volume:13 ; number:1 ; day:25 ; month:10 ; year:2023 ; pages:1-11 ; date:12.2023
Scientific reports ; 13, Heft 1 (25.10.2023), 1-11, 12.2023
- Creator
-
Kim, Minwook
So, Juhoon
Shin, Donghun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-44935-5
- URN
-
urn:nbn:de:101:1-2024020907464449490906
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Minwook
- So, Juhoon
- Shin, Donghun
- SpringerLink (Online service)
Other Objects (12)
PPARα alleviates iron overload‐induced ferroptosis in mouse liver
Modulation of liver steatosis by miR-21/PPARα
Transcriptional profiling of PPARα−/− and CREB3L3−/− livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPARα
NUAK2 is a critical YAP target in liver cancer
The role of YAP/Yorkie during compensatory liver regeneration
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice
YAP activation drives liver regeneration after cholestatic damage induced by rbpj deletion
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Bile canaliculi remodeling activates YAP via the actin cytoskeleton during liver regeneration
PPARα alleviates iron overload‐induced ferroptosis in mouse liver
Modulation of liver steatosis by miR-21/PPARα
Transcriptional profiling of PPARα−/− and CREB3L3−/− livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPARα
NUAK2 is a critical YAP target in liver cancer
The role of YAP/Yorkie during compensatory liver regeneration
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice
YAP activation drives liver regeneration after cholestatic damage induced by rbpj deletion
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Bile canaliculi remodeling activates YAP via the actin cytoskeleton during liver regeneration
PPARα alleviates iron overload‐induced ferroptosis in mouse liver
Modulation of liver steatosis by miR-21/PPARα
Transcriptional profiling of PPARα−/− and CREB3L3−/− livers reveals disparate regulation of hepatoproliferative and metabolic functions of PPARα
NUAK2 is a critical YAP target in liver cancer
The role of YAP/Yorkie during compensatory liver regeneration
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice
YAP activation drives liver regeneration after cholestatic damage induced by rbpj deletion
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression